Absorption and Distribution of Glucosamine and Chondroitin
Information source: National Center for Complementary and Alternative Medicine (NCCAM)
Information obtained from ClinicalTrials.gov on August 03, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoarthritis
Intervention: Glucosamine (Drug); Chondroitin (Drug)
Phase: N/A
Status: Completed
Sponsored by: National Center for Complementary and Alternative Medicine (NCCAM) Official(s) and/or principal investigator(s):
Christopher G. Jackson, MD, Principal Investigator, Affiliation: University of Utah
Summary
The purpose of this study is to examine the way the dietary supplements glucosamine and chondroitin are absorbed and distributed throughout the body.
Clinical Details
Official title:
A Pharmacokinetic Study of Glucosamine and Chondroitin
Study design: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics Study
Detailed description:
Osteoarthritis is the most common musculoskeletal disease in the world. While predisposing conditions have been identified, the actual cause of osteoarthritis remains unknown. Traditional treatments, most often anti-inflammatory drugs and pain relievers, produce variable results and may cause significant toxicity. The use of complementary and alternative therapies in the treatment of osteoarthritis has become more common, and particular interest has focused on glucosamine and chondroitin treatments. This study will examine the pharmacokinetics of glucosamine and chondroitin.
This study consists of two phases. In Phase I, participants will have two study visits, during which multiple blood samples will be taken to determine levels of glucosamine and chondroitin found naturally in the body. During Phase II, participants will be randomly assigned to receive glucosamine, chondroitin, or a combination of the two for 3 months. Blood samples will be taken at each of the three Phase II study visits to examine the pharmacokinetics of glucosamaine and chondroitin.
Eligibility
Minimum age: 21 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Able to walk
Exclusion Criteria:
- Allergy to glucosamine, chondroitin, or shellfish
- Liver or kidney disease
- Diabetes mellitus
- Concurrent use of other complementary or alternative therapies
Locations and Contacts
University of Utah Health Sciences Center, Salt Lake City, Utah 84132, United States
Additional Information
Starting date:
April 2004
Ending date: January 2006
Last updated: August 16, 2006
|
